Onyx sues Bayer over Nexavar variant
This article was originally published in Scrip
Executive Summary
Onyx Pharmaceuticals has sued Bayer in the US District for the Northern District of California, asserting that a Phase II anticancer compound – a variant of the multi-targeted kinase inhibitor Nexavar (sorafenib) developed under a collaboration – is jointly owned by the companies.